Related Experiment Videos
Prevalence of anticardiolipin antibodies in peripheral arterial thrombosis
J M de Godoy1, M F de Godoy, D M Braile
1Department of Cardiology and Vascular Surgery, São José do Rio Preto University School of Medicine, São Paulo, Brasil. godoyjmp@riopreto.com.br
Insights
Peripheral arterial thrombosis patients show a high prevalence of anticardiolipin antibodies. This study confirms a significant link between these antibodies and arterial thrombosis, aiding in risk assessment.
Area of Science:
- Immunology
- Vascular Medicine
- Thrombosis Research
Background:
- Anticardiolipin antibodies are associated with thrombosis.
- Their prevalence in peripheral arterial thrombosis requires further investigation.
Purpose of the Study:
- To prospectively evaluate the prevalence of anticardiolipin antibodies in patients diagnosed with peripheral arterial thrombosis.
- To compare antibody levels in patients versus a healthy control group.
Main Methods:
- Prospective study of 59 patients with peripheral arterial thrombosis and 100 healthy blood donors.
- Anticardiolipin antibodies were quantified using immunoassay enzyme methods and dilution techniques.
Main Results:
- Anticardiolipin antibodies were detected in 62.7% of patients with peripheral arterial thrombosis (28.8% positive, 33.9% borderline).
- In the control group, only 1% were positive and 6% borderline.
- The increased prevalence in patients was statistically significant (p < 0.001).
Conclusions:
- Peripheral arterial thrombosis is significantly associated with a high prevalence of anticardiolipin antibodies.
- These findings suggest anticardiolipin antibodies may be a relevant biomarker for peripheral arterial thrombosis.
Abstract:
The aim of this study was to assess prospectively the prevalence of anticardiolipin antibodies in patients with peripheral arterial thrombosis. Fifty-nine patients with arterial thrombosis (38 men, 21 women), ages ranging from 24 to 80 years, mean age, 45.5 years, were studied. The control group included 100 volunteer blood donors. After confirmation of the thrombotic event, anticardiolipin antibodies were dosed by the immunoassay enzyme method and by dilution. In Group I these antibodies were present in 62.7% of the patients, of which 33.9% were borderline and 28.8% were positive. In the control group 6% of the patients were borderline and 1% was positive. The statistical analysis showed that the prevalence found was statistically significant (p < 0.001), even when the borderline titers were not considered positive. Patients with peripheral arterial thrombosis have a high prevalence of anticardiolipin antibodies.